• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Context Therapeutics Inc. (Amendment)

    2/7/24 4:24:50 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTX alert in real time by email
    SC 13G/A 1 cntx-schedule13g_amlehr.htm SC 13G/A Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    Context Therapeutics Inc.
    (Name of Issuer)
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
    21077P108
    (CUSIP Number)
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

        ☐ Rule 13d-1(b)

        ☐ Rule 13d-1(c)

        ☒ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (continued on the following pages)












    CUSIP No. 21077P10813G

    1
    NAMES OF REPORTING PERSONS

        Martin Lehr
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a) ☐
        
    (b) ☒
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

        United States


    NUMBER OF
    5
    SOLE VOTING POWER

      632,276 (1)
    SHARES
    BENEFICIALLY
    OWNED BY
    6
    SHARED VOTING POWER

      820,190 (2)
    EACH
    REPORTING
    PERSON
    7
    SOLE DISPOSITIVE POWER

      632,276 (1)
    WITH:
    8
    SHARED DISPOSITIVE POWER

       820,190 (2)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

        1,452,466 (1)(2)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐

        N/A
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

        8.8% (1)(2)(3)
    12
    TYPE OF REPORTING PERSON (See Instructions)

        IN
    ________
    (1) Consists of (i) 472,575 shares of the Issuer’s common stock underlying options held directly by Mr. Lehr that are exercisable within 60 days of December 31, 2023 (the “Option Shares”) and (ii) 159,701 shares of the Issuer’s common stock held directly by Mr. Lehr.
    (2) Represents shares of the Issuer’s common stock held by the Martin Lehr 2000 Trust.
    (3) Based upon 15,966,053 shares of the Issuer’s common stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023, plus the Option Shares.




    CUSIP No. 21077P10813G


    1
    NAMES OF REPORTING PERSONS

    Martin Lehr 2000 Trust
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a) ☐
        
    (b) ☒
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

        Pennsylvania


    NUMBER OF
    5
    SOLE VOTING POWER

    0
    SHARES
    BENEFICIALLY
    OWNED BY
    6
    SHARED VOTING POWER

     820,190
    EACH
    REPORTING
    PERSON
    7
    SOLE DISPOSITIVE POWER

    0
    WITH:
    8
    SHARED DISPOSITIVE POWER

    820,190
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

        820,190
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐

        N/A
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

        5.1% (1)
    12
    TYPE OF REPORTING PERSON (See Instructions)

        OO
    ________
    (1) Based upon 15,966,053 shares of the Issuer’s common stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.




    CUSIP No. 21077P10813G


    1
    NAMES OF REPORTING PERSONS

    Ellyn Lehr
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a) ☐
        
    (b) ☒
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

        Pennsylvania


    NUMBER OF
    5
    SOLE VOTING POWER

    0
    SHARES
    BENEFICIALLY
    OWNED BY
    6
    SHARED VOTING POWER

     820,190 (1)
    EACH
    REPORTING
    PERSON
    7
    SOLE DISPOSITIVE POWER

    0
    WITH:
    8
    SHARED DISPOSITIVE POWER

    820,190 (1)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

        820,190 (1)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐

        N/A
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

        5.1% (1)(2)
    12
    TYPE OF REPORTING PERSON (See Instructions)

        IN
    ________
    (1) Represents shares of the Issuer’s common stock held by the Martin Lehr 2000 Trust.
    (2) Based upon 15,966,053 shares of the Issuer’s common stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.





    Item 1.
        (a)    Name of Issuer
    Context Therapeutics Inc. (the “Issuer”)
        (b)    Address of Issuer’s Principal Executive Offices
    2001 Market Street, Suite 3915, Unit #15
    Philadelphia, Pennsylvania 19103
    Item 2.
        (a)    Name of Person Filing
    This Schedule 13G is being filed by Martin Lehr, the Martin Lehr 2000 Trust and Ellyn Lehr.
        (b)    Address of Principal Business Office or, if none, Residence
    (i)Martin Lehr:         2001 Market Street, Suite 3915, Unit #15
                Philadelphia, Pennsylvania 19103
    (ii)Martin Lehr 2000 Trust:     2001 Market Street, Suite 3915, Unit #15
                Philadelphia, Pennsylvania 19103
    (iii)Ellyn Lehr:         2001 Market Street, Suite 3915, Unit #15
                Philadelphia, Pennsylvania 19103
        (c)    Citizenship
    (i) Martin Lehr: United States
    (ii) Martin Lehr 2000 Trust: Pennsylvania
    (iii) Ellyn Lehr: United States
        (d)    Title of Class of Securities
    Common stock, par value $0.001 per share
        (e)    CUSIP Number
    21077P108
    Item 3.    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
        (a)    ☐    Broker or dealer registered under section 15 of the Act.
        (b)    ☐    Bank as defined in section 3(a)(6) of the Act.
        (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act.
        (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940.
        (e)    ☐    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).
        (f)    ☐    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F).
        (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).
        (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.



        (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.
        (j)    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
        (k)    ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
    Item 4.    Ownership
        (a)    Amount Beneficially Owned
    (i) Martin Lehr:            1,452,466 shares*
    (ii) Martin Lehr 2000 Trust:     820,190 shares**
    (iii) Ellyn Lehr:             820,190 shares**
    * Consists of (i) 820,190 shares of the Issuer’s common stock held by the Martin Lehr 2000 Trust, (ii) 472,575 shares of the Issuer’s common stock underlying options held directly by Mr. Lehr that are exercisable within 60 days of December 31, 2023 (the “Option Shares”) and (iii) 159,701 shares of the Issuer’s common stock held directly by Mr. Lehr.
    ** Represents shares of the Issuer’s common stock held by the Martin Lehr 2000 Trust.
        (b)    Percent of Class
    (i) Martin Lehr:         8.8%
    (ii) Martin Lehr 2000 Trust: 5.1%
    (iii) Ellyn Lehr:          5.1%
    Based upon 15,966,053 shares of the Issuer’s common stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023, plus, in the case of Mr. Lehr, the Option Shares.
        (c)    Number of shares as to which such person has:
    (i)     Sole power to vote or to direct the vote
    (A) Martin Lehr:            632,276
    (B) Martin Lehr 2000 Trust:    0
    (C) Ellyn Lehr:            0
    (ii)      Shared power to vote or to direct the vote
    (A) Martin Lehr:            820,190
    (B) Martin Lehr 2000 Trust:    820,190
    (C) Ellyn Lehr:            820,190
    (iii) Sole power to dispose or to direct the disposition of
    (A) Martin Lehr:            632,276
    (B) Martin Lehr 2000 Trust:    0
    (C) Ellyn Lehr:            0
    (iv)     Shared power to dispose or to direct the disposition of



    (A) Martin Lehr:            820,190
    (B) Martin Lehr 2000 Trust:    820,190
    (C) Ellyn Lehr:            820,190
    Item 5.    Ownership of Five Percent or Less of a Class
        If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
    Not Applicable
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
    Not Applicable
    Item 8.    Identification and Classification of Members of the Group
    Not Applicable
    Item 9.    Notice of Dissolution of Group
    Not Applicable
    Item 10.    Certification
    Not Applicable




    SIGNATURE
        After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:    February 7, 2024


    MARTIN LEHR


    By: /s/ Martin Lehr    
    Name: Martin Lehr


    MARTIN LEHR 2000 TRUST


    By: /s/ Ellyn Lehr    
    Name: Ellyn Lehr
    Title: Trustee



    ELLYN LEHR


    By:/s/ Ellyn Lehr        
    Name: Ellyn Lehr









    EXHIBIT INDEX
     
    Exhibit NumberExhibit
    99.1
    Joint Filing Agreement, dated February 14, 2023, by and among Martin Lehr, the Martin Lehr 2000 Trust and Ellyn Lehr (incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by Martin Lehr with the Securities and Exchange Commission on February 14, 2023)



    Get the next $CNTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNTX

    DatePrice TargetRatingAnalyst
    9/18/2025$5.00Buy
    Guggenheim
    4/21/2025Outperform
    William Blair
    1/8/2025$4.00Mkt Outperform
    JMP Securities
    11/25/2024$9.00Buy
    D. Boral Capital
    5/16/2024$4.50Overweight
    Piper Sandler
    2/2/2022$6.00Buy
    HC Wainwright & Co.
    1/24/2022$10.00Buy
    ThinkEquity
    More analyst ratings

    $CNTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Lehr Martin A. bought $70,080 worth of shares (100,000 units at $0.70) (SEC Form 4)

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/10/25 5:26:21 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer, Corp. Sec Levit Alex C. bought $11,520 worth of shares (20,000 units at $0.58), increasing direct ownership by 222% to 29,000 units (SEC Form 4)

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/10/25 5:23:47 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Minai-Azary Jennifer Lynn bought $25,486 worth of shares (40,010 units at $0.64), increasing direct ownership by 100% to 80,010 units (SEC Form 4)

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/10/25 5:22:20 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

    PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today shared two posters discussing the Company's CT-95 and CT-202 programs at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, being held November 7–9, 2025 in National Harbor, MD. CT-95 and CT-202 Highlights and Near-Term Milestones CT-95: Mesothelin x CD3 bispecific TCE CT-95 is avidity enhanced and affinity tuned to localize therapeutic activity to the tumor microenvironment.In an ongoing Phase 1 trial, Context has enrolled 6 patie

    11/7/25 7:30:00 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

    Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 million as of September 30, 2025 PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today provided a clinical update and reported its financial results for the third quarter ended September 30, 2025. "We believe the early clinical data for CTIM-76 provides encouraging early signs of antitumor activity

    11/5/25 4:15:57 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

    Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product' strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma's recently announced €38 million Series C financing Saint-Genis-Pouilly, France, 28 October 2025 – Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Karen L. Smith, MD, PhD, MBA, LLM a

    10/28/25 8:00:00 AM ET
    $CNTX
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Context Therapeutics Inc.

    SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/25 4:27:33 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Context Therapeutics Inc.

    SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/25 1:16:53 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Context Therapeutics Inc. (0001842952) (Filer)

    11/5/25 4:21:13 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pasternak Andy

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/12/25 5:30:09 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kantoff Philip W.

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/12/25 5:28:39 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Smith Karen L.

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/12/25 5:27:03 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Context Therapeutics with a new price target

    Guggenheim initiated coverage of Context Therapeutics with a rating of Buy and set a new price target of $5.00

    9/18/25 8:39:06 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Context Therapeutics

    William Blair initiated coverage of Context Therapeutics with a rating of Outperform

    4/21/25 8:38:14 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on Context Therapeutics with a new price target

    JMP Securities initiated coverage of Context Therapeutics with a rating of Mkt Outperform and set a new price target of $4.00

    1/8/25 7:37:35 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    Leadership Updates

    Live Leadership Updates

    View All

    Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

    Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product' strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma's recently announced €38 million Series C financing Saint-Genis-Pouilly, France, 28 October 2025 – Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Karen L. Smith, MD, PhD, MBA, LLM a

    10/28/25 8:00:00 AM ET
    $CNTX
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

    PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer ("CMO"), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company's Board of Directors ("Board"). Dr. Chagin brings over a decade of leadership in clinical development and regulatory strategy for T cell therapies in solid tumors at Adaptimmune Therapeutics plc ("Adaptimmune") and Tmunity

    5/29/25 7:30:05 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

    Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into next phase of growth PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who stepped down from the Board effective January 12, 2025.  "I am honored to become the next Chairman of the Board of Directors of Context, where I expect to leverage my experience advising and building fully int

    1/13/25 7:30:07 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    Financials

    Live finance-specific insights

    View All

    Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

    CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2025, and reported on recent and upcoming business highlights. "We remain focused on progressing our clinical pipeline — CTIM-76, a selective Claudin 6 ("CLDN6") x CD3 bispecific an

    8/6/25 4:11:01 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

    CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2025, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, "We continue to advance our clinical pipeline and are pleased to have two product c

    5/7/25 4:09:57 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Reports Full Year 2024 Operating and Financial Results

    CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, "We believe 2024 was a transformative year for Context, marked by strategic acquisitions, a s

    3/20/25 4:22:37 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

    SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:31:29 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Context Therapeutics Inc.

    SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:05:15 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

    SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 4:52:28 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care